BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1240 related articles for article (PubMed ID: 17461862)

  • 1. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
    Kaplan JE; Hanson DL; Cohn DL; Karon J; Buskin S; Thompson M; Fleming P; Dworkin MS;
    Clin Infect Dis; 2003 Oct; 37(7):951-8. PubMed ID: 13130408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.
    Bisson GP; Gross R; Strom JB; Rollins C; Bellamy S; Weinstein R; Friedman H; Dickinson D; Frank I; Strom BL; Gaolathe T; Ndwapi N
    AIDS; 2006 Aug; 20(12):1613-9. PubMed ID: 16868442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
    Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
    HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3.
    Hulgan T; Raffanti S; Kheshti A; Blackwell RB; Rebeiro PF; Barkanic G; Ritz B; Sterling TR
    J Infect Dis; 2005 Sep; 192(6):950-7. PubMed ID: 16107946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.
    Moore DM; Hogg RS; Chan K; Tyndall M; Yip B; Montaner JS
    AIDS; 2006 Feb; 20(3):371-7. PubMed ID: 16439870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
    Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
    Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
    Tarwater PM; Gallant JE; Mellors JW; Gore ME; Phair JP; Detels R; Margolick JB; Muñoz A
    AIDS; 2004 Dec; 18(18):2419-23. PubMed ID: 15622318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.